Skip to main content
SpringerLink
Log in
Book cover

Hormones and the Heart in Health and Disease pp 235–251Cite as

Androgen and Estrogen Effects on Plasma Lipids in Men

  • Chapter

  • 94 Accesses

Part of the book series: Contemporary Endocrinology ((COE,volume 21))

Abstract

It is widely appreciated that premenopausal women have a lower risk for coronary artery disease (CAD) than do men, and that this risk increases in postmenopausal women (1,2).The effects of estrogens on plasma lipids and other factors affecting coronary risk in women have been studied extensively, and are reviewed elsewhere (3–5). The contributions of gonadal steroids to coronary risk in men have received less attention. This chapter reviews the effects of androgens and estrogen on plasma lipids and relates these data to the increased coronary risk associated with male gender.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984; 76A: 4–12.

    Article  PubMed  CAS  Google Scholar 

  2. Knopp RH. Effects of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease in women. Obstet Gynecol 1988; 72: 295–305.

    Google Scholar 

  3. Knopp RH, Zhu X, Bonet B, Bagatell CJ. Effect of sex steroid hormones and lipoproteins, clotting, and the arterial wall. Semin Reprod Endocrinol 1996; 14: 15–27.

    Article  PubMed  CAS  Google Scholar 

  4. Sacks FM, Gerhard M, Walsh BW. Sex hormones, lipoproteins, and vascular reactivity. Curr Opin Lipidol 1995; 6: 161–165.

    Article  PubMed  CAS  Google Scholar 

  5. Knopp RH, Zhu X, Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis 1994; 110: S83 - S91.

    Article  PubMed  CAS  Google Scholar 

  6. Bagatell CJ, Bremner WJ. Androgens in men: uses and abuses. N Engl J Med 1996; 334: 707–714.

    Article  PubMed  CAS  Google Scholar 

  7. Wu FWC. Testicular steroidogenesis. Ballieres Clin Endocrinol Metab 1992; 6: 373–403.

    Article  CAS  Google Scholar 

  8. Beaglehole R, Trost DC, Tamir I, Kwiterovich P, Glueck CJ, Insull W, Christensen B. Plasma high-density lipoprotein cholesterol in children and young adults. The Lipid Research Clinics Program Prevalence study. Circulation 1980; 62 (Suppl 4): 83–92.

    CAS  Google Scholar 

  9. Berenson GS, Srinivasan SR, Cresanta JL, Foster TA, Webber LS. Dynamic changes in serum lipoproteins in children during adolescence and sexual maturation. Am J Epidemiol 1981; 113: 157–170.

    PubMed  CAS  Google Scholar 

  10. Kirkland RT, Keenan BS, Probstfield JL, Patsch W, Lin TL, Clayton GW, et al. Decrease in plasma high-density lipoprotein cholesterol levels at puberty in boys with delayed adolescence. JAMA 1987; 257: 502–507.

    Article  PubMed  CAS  Google Scholar 

  11. Freedman DS, Cresanta JL, Srinivian SR, Webber LS, Berenson GS. Longitudinal serum lipoprotein changes in white males during adolescence: the Bogalusa Heart Study. Metabolism 1985; 34: 396–403.

    Article  PubMed  CAS  Google Scholar 

  12. Morrison JA, Laskarzewski PM, Rauh JL, Brookman R, Mellies M, Frazer M, et al. Lipids, lipoproteins, and sexual maturation during adolescence: the Princeton maturation study. Metabolism 1979; 28: 641–648.

    Article  PubMed  CAS  Google Scholar 

  13. Stozicky F, Slaby P, Volenikova L. Longitudinal study of serum cholesterol apolipoproteins and sex hormones during puberty. Acta Pediatr Scand 1991; 80: 1139–1144.

    Article  CAS  Google Scholar 

  14. Crook D, Seed M. Endocrine control of plasma lipoprotein metabolism: effects of gonadal steroids. Ballieres Clin Endocrinol Metab 1990; 4: 851–875.

    Article  CAS  Google Scholar 

  15. Heiss G, Tamir I, Davis CE, Tyroler HS, Rifkind BM, Schonfeld G, et al. Lipoprotein-cholesterol distributions in selected North American population: the Lipid Research Clinics Program Prevalence Study. Circulation 1980; 61: 302–315.

    Article  PubMed  CAS  Google Scholar 

  16. Lipid Research Clinics. Population Studies Data Book, vol. 1: the Prevalence Study. Dept. of Health and Human Services, 1980.

    Google Scholar 

  17. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: the Massachusetts male aging study. J Clin Endocrinol Metab 1991; 73: 1016–1025.

    Article  PubMed  CAS  Google Scholar 

  18. Vermeulen A. Androgens in the aging male. J Clin Endocrinol Metab 1991; 73: 221–224.

    Article  PubMed  CAS  Google Scholar 

  19. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men: a prospective population based study. Circulation 1988; 78: 539–545.

    Article  PubMed  CAS  Google Scholar 

  20. Duell PB, Bierman EL. Relationship between sex hormones and high-density lipoprotein cholesterol levels in healthy adult men. Arch Int Med 1990; 150: 2317–2320.

    Article  CAS  Google Scholar 

  21. Norday A. Sex hormones and high density lipoproteins in healthy males. Atherosclerosis 1979; 34: 431–436.

    Article  Google Scholar 

  22. Dai WS, Gutai JP, Kuller LH, Laporte RE, Falvo-Gerard L, Caggiula A. Relation between high-density lipoprotein cholesterol and sex hormone concentrations in men. Am J Cardiol 1984; 53: 1259–1263.

    Article  PubMed  CAS  Google Scholar 

  23. Semmens J, Rouse I, Beilin LJ, Masarec JRL. Relationship of plasma HDL-cholesterol to testosterone, estradiol, and sex-hormone binding globulin levels in men and women Metabolism 1983; 32: 28–32.

    Google Scholar 

  24. Heller RF, Wheeler MJ, Micalleff J, Miller NE, Lewis B. Relationship of high density lipoprotein cholesterol with total and free testosterone and sex hormone binding globulin. Acta Endocrinol (Copenhagen) 1983; 104: 253–256.

    CAS  Google Scholar 

  25. Kiel DP, Plymate SR. Sex hormones and lipoproteins in men. Am J Med 1989; 87: 35–39.

    Article  PubMed  CAS  Google Scholar 

  26. Khaw KT, Barrett-Connor E. Endogenous sex hormones, high density lipoprotein cholesterol and other lipoprotein fractions in men. Arteriosclerosis Thromb 1991; 11: 489–494.

    Article  CAS  Google Scholar 

  27. Lichtenstein M, Yarnell JWG, Elwood PC, Beswick AD, Sweetnam PM, Marks V. Sex hormones, insulin, lipids and prevalent ischemic heart disease. Am J Epidemiol 1987; 12: 647–657.

    Google Scholar 

  28. Stefanick ML, Williams PT, Krauss RM, Terry RB, Vranizan KM, Wood PD. Relationships of plasma estradiol, testosterone, and sex hormone-binding globulin with lipoproteins, apolipoproteins, and high density lipoprotein subfractions in men. J Clin Endocrinol Metab 1987; 64: 723–729.

    Article  PubMed  CAS  Google Scholar 

  29. Freeman DS, O’Brien TR, Flanders WD, DeStafano F, Barboriak JJ. Relation of serum testosterone levels to high density lipoprotein cholesterol and other characteristics in men. Arteriosclerosis Thromb 1991; 11: 307–315.

    Article  Google Scholar 

  30. Mendoza SG, Osuna A, Zerpa A, Gartside PS, Gleuck CJ. Hypertriglyceridemia and hypoalphalipoproteinemia in azoospermic and oligospermic young men: relationships of endogenous testosterone to triglyceride and high density lipoprotein cholesterol metabolism. Metabolism 1981; 30: 481–489.

    Article  PubMed  CAS  Google Scholar 

  31. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin dependent diabetes mellitus. Ann Int Med 1992; 117: 807–811.

    PubMed  CAS  Google Scholar 

  32. Hamalainen E, Tikkanen H, Harkonen M, Naveri H, Aldercreutz, H. Serum lipoproteins, sex hormones and sex hormone binding globulin in middle-aged men of different physical fitness and risk of coronary heart disease. Atherosclerosis 1987; 67: 155–162.

    Article  PubMed  CAS  Google Scholar 

  33. Lindholm J, Winkel P, Brodthagen U, Gyntelberg F. Coronary risk factors and plasma sex hormones. Am J Med 1982; 73: 648–651.

    Article  PubMed  CAS  Google Scholar 

  34. Gutai J, LaPorte R, Kuller L, Dai W, Falvo-Gerard L, Caggiula A. Plasma testosterone, high density lipoprotein cholesterol and other lipoprotein fractions. Am J Cardiol 1981; 48: 896–901.

    Article  Google Scholar 

  35. Miller GJ, Wheeler MJ, Price SGL, Beckles GLA, Kirkwood BR, Carson DC. Serum high density lipoprotein subclasses, testosterone and sex-hormone binding globulin in Trinidadian men of African and Indian descent. Athersclerosis 1985; 55: 251–258.

    Article  CAS  Google Scholar 

  36. Deutscher S, Bates MW, Caines MJ, LaPorte RE, Puntereri A, Taylor FH. Determinants of lipid and lipoprotein level in elderly men. Atherosclerosis 1986; 60: 221–229.

    Article  PubMed  CAS  Google Scholar 

  37. Dioyssiou-Asteriou A, Katimertzi M. Endogenous testosterone and serum apolipoprotein (a) levels. Atherosclerosis 1993; 100: 123–126.

    Article  Google Scholar 

  38. Oppenheim DS, Greenspan SL, Zervas N, Schoenfeld DA, Klibanski A. Elevated serum lipids in hypogonadal men with and without hyperprolactinemia. Ann Int Med 1989; 111: 288–292.

    PubMed  CAS  Google Scholar 

  39. Hamalainen E, Aldercreutz, H, Ehnholm C, Puska P. Relationship of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men. Metabolism 1986; 35: 535–541.

    Article  PubMed  CAS  Google Scholar 

  40. Yarnell JWG, Beswick AD, Sweetnam PM, Riad-Fahmy D. Endogenous Sex hormones and ischemic heart disease in men: the Caerphilly prospective study. Arteriosclerosis Thromb 1993; 13: 517–520.

    Article  CAS  Google Scholar 

  41. Furman RH, Howard RP, Imagawa R. Serum lipid and lipoprotein concentrations in castrate and noncastrate male subjects. Circulation 1956; 14: 490.

    Google Scholar 

  42. Karten MJ, Rivier JE. Gonadotropin releasing hormone analog design. Structure function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 1986; 7: 44–66.

    Article  PubMed  CAS  Google Scholar 

  43. Moorjani S, Dupont A, Labrie F, Lupien PJ, Brun D, Gagne C, et al. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism 1987; 36: 244–250.

    Article  PubMed  CAS  Google Scholar 

  44. Moorjani S, Dupont A, Labrie F, Lupien PJ, Gagne C, Brun D, et al. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab 1988; 66: 614–621.

    Article  Google Scholar 

  45. Goldberg RB, Rabin D, Alexander A, Doelle N, Getz GS. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins Al and AII. J Clin Endocrinol Metab 1985; 60: 203–207.

    Article  PubMed  CAS  Google Scholar 

  46. Byerley L, Lee WN, Swerdloff RS, Buena F, Nair SK, Buchanan TA, et al. Effect of modulating serum testosterone levels in the normal male range on protein, carbohydrate, and lipid metabolism in men: implications for testosterone replacement therapy. Endocr J 1993; 1: 253–262.

    Google Scholar 

  47. Bagatell CJ, Knopp RH, Vale WW, Rivier JE, Bremner WJ. Physiologic levels of testosterone suppress HDL cholesterol levels in normal men. Ann Int Med 1992; 116: 967–973.

    PubMed  CAS  Google Scholar 

  48. Bagatell CJ, Bremner WJ. Androgen and progestagen effects on plasma lipids. Prog Cardiovasc Disc 1995; 38: 255–271.

    Article  CAS  Google Scholar 

  49. Pavlou SN, Brewer K, Lindner J, Farley MG, Bastias C, Rogers BJ, et al. Combined administration of a gonadotropin releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab 1991; 73: 1360–1369.

    Article  PubMed  CAS  Google Scholar 

  50. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels. Opposite effects of estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992; 89: 1166–1171.

    Article  PubMed  CAS  Google Scholar 

  51. Arrer E, Jungwirth A, Mack D, Frick J, Patsch W. Treatment of prostate cancer with gonadotropin releasing hormone analogue: effect on lipoprotein (a). J Clin Endocrinol Metab 1996; 81: 2508–2511.

    Article  PubMed  CAS  Google Scholar 

  52. Denti L, Pasolinii G, Cortellini P, Ferretti S, Sanfelici L, Ablondi F, Valenti G. Effects of androgen suppression by gonaotropin releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein (a). Clin Chem 1996; 42: 1176–1181.

    PubMed  CAS  Google Scholar 

  53. Mooradian AD, Morley JE, Korenman SG. Biological effects of androgens. Endocr Rev 1987; 7: 1–28.

    Article  Google Scholar 

  54. Sorva R, Kuusi T, Taskinen M-R, Perheentupa J, Nikkila EA. Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 1988; 69: 191–197.

    Article  PubMed  CAS  Google Scholar 

  55. Jones DB, Higgins B, Billet JS, Price WH, Edwards CRW, Beastall GH, et al. The effect of testosterone replacement on plasma lipids and lipoproteins. European J Clin Invest 1989; 19: 438–441.

    Article  CAS  Google Scholar 

  56. Ozata M, Yildirimkaya M, Bulur M, Yilmaz K, Bolu E, Corakci A, Gundogan A. Effects of gonaotropin and testosterone treatments on lipoprotein (a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 1996; 81: 3372–3378.

    Article  PubMed  CAS  Google Scholar 

  57. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–1098.

    Article  PubMed  CAS  Google Scholar 

  58. Morley JE, Perry M, Kaiser FE, Kraenzle D, Jensen J, Houston K, et al. Effects of testosterone replacement therapy in older hypogonadal males: a preliminary study. J Am Geriat Soc 1993; 41: 149–152.

    PubMed  CAS  Google Scholar 

  59. Paulsen CA, Bremner WJ, Leonard J. Male contraception: clinical trials, In: Mishell DR, ed. Advances in Fertility Research. Raven, New York. 1982, pp. 157–170.

    Google Scholar 

  60. Matsumoto A. Effects of chronic testosterone administration in normal men: safety and efficacy of high-dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab 1990; 70: 282–287.

    Article  PubMed  CAS  Google Scholar 

  61. World Health Organization Task Force on Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990; 336: 955–959.

    Article  Google Scholar 

  62. Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ. Comparison of a gonadotropin releasing hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab 1993; 77: 427–432.

    Article  PubMed  CAS  Google Scholar 

  63. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Matsumoto AM. Combined adminstration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 1996; 81: 757–762.

    Article  PubMed  CAS  Google Scholar 

  64. Friedl KE, Hannan CJ, Jones RE, Kettler TM, Plymate SR. High-density lipoprotein is not decreased if an aromatizable androgen is administered. Metabolism 1990; 39: 69–77.

    Article  PubMed  CAS  Google Scholar 

  65. Thompson PD, Cullinane EM, Sady SP, Chevenevert C, Saritelli AL, Sady MA, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261: 1165–1168.

    Article  PubMed  CAS  Google Scholar 

  66. Zmuda JN, Fahrenbach MC, Younkin BT, Bausserman LL, Terry RB, Catlin DH, et al. Effect of testosterone aromatization on high-density lipoprotein cholesterol level and post-heparin lipolytic activity. Metabolism 1993; 42: 446–450.

    Article  PubMed  CAS  Google Scholar 

  67. Bagatell CJ, Heiman JR, Matsumoto A, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high dose, exogenous testosterone (T) in normal men. J Clin Endocrinol Metab 1994; 79: 561–567.

    Article  PubMed  CAS  Google Scholar 

  68. Meriggiola MC, Marcovina S, Paulsen CA, Bremner WJ. Testosterone enanthate at the dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int J Androl 1995; 18: 237–242.

    PubMed  CAS  Google Scholar 

  69. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al. Effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1–7.

    Article  PubMed  CAS  Google Scholar 

  70. Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ. Testosterone induced suppression of lipoprotein (a) in normal men; relation to basal lipoprotein (a) level. Atherosclerosis 1996; 122: 89–95.

    Article  PubMed  CAS  Google Scholar 

  71. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein (a) in men. Am J Cardiol 1996; 77: 1244–1247.

    Article  CAS  Google Scholar 

  72. Anderson RA, Wallace EM, Wu FC. Effect of testosterone enanthate on serum lipoproteins in men. Contraception 1995; 52: 115–119.

    Article  PubMed  CAS  Google Scholar 

  73. Berglund L, Carlstrom K, Reinhard S, Gottlieb C, Eriksson M, Angelin B, Henrikkson P. Hormonal regulation of serum liporotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 1996; 81: 2633–2637.

    Article  PubMed  CAS  Google Scholar 

  74. Alen M, Rahlika P, Marniemi J. Serum lipids in power athletes self-administering testosterone and anabolic steroids. Int J Sports Med 1985; 6: 139–144.

    Article  PubMed  CAS  Google Scholar 

  75. Kantor MA, Bianchini A, Bernier D, Sady SP, Thompson PD. Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity. Med Sci Sports Exerc 1985; 144: 62–65.

    Google Scholar 

  76. Haffner SM, Kushwaha RS, Foster DM, Applebaum-Bowden D, Hazzard W. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism 1983; 32: 413–420.

    Article  PubMed  CAS  Google Scholar 

  77. Taggart HM, Applebaum-Bowden D, Haffner S, Warnick GR, Cheung MC, Albers JJ, et al. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. Metabolism 1982; 31: 1147–1152.

    Article  PubMed  CAS  Google Scholar 

  78. Hazzard WR, Haffner SM, Kushwaha RS, Applebaum-Bowden D, Foster DM. Preliminary report: kinetic studies on the modulation of high-density lipoprotein, apolipoprotein, and subfraction metabolism by sex steroids in a post-menopausal woman. Metabolism 1984; 33: 779–784.

    Article  PubMed  CAS  Google Scholar 

  79. Gleuck CJ, Swanson F, Fishbak J. Effects of oxandrolone on plasma triglycerides and post-heparin lipolytic activity in patients with types II, IV, and V hyperlipoproteinemia. Metabolism 1971; 20: 691–702.

    Google Scholar 

  80. Crook D, Sidhu M, Seed M, O’Donnell MO, Stevenson JC. Lipoprotein (a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992; 92: 41–47.

    Article  PubMed  CAS  Google Scholar 

  81. Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chestnut CH, Hazzard WR. Reduction of lecithin-cholesterol acyltransferase, apoprotein D and the Lp(a) lipoprotein with the anabolic steroid, stanozolol. Biochim Biophys Acta 1984; 795: 293–296.

    Article  PubMed  CAS  Google Scholar 

  82. Bagatell CJ, Knopp RH, Bremner WJ. Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men. J Clin Endocrinol Metab 1994; 78: 855–861.

    Article  PubMed  CAS  Google Scholar 

  83. Erikson M, Berglund L, Rudling M, Henriksson P, Angelin B. Effect of estrogen on low density lipoprotein metabolism in males. J Clin Invest 1989; 84: 802–810.

    Article  Google Scholar 

  84. Bulusu NV, Leis S, Das S, Clayton WE. Serum lipid changes after estrogen therapy in prostatic carcinoma. Urology 1982; 20: 147–150.

    Article  PubMed  CAS  Google Scholar 

  85. Rossner S, Hedlund P-O. Jogestrand T, Sawe U. Treatment of prostatic cancer: effets of serum lipoproteins and the cardiovascular system. J Urol 1985; 133: 53–57.

    PubMed  CAS  Google Scholar 

  86. Blackard CE, Doe RP, Mellinger GT, Byar DP. Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 1970; 25: 249–256.

    Article  Google Scholar 

  87. Veterans Administration Co-operataive Urological Research Group. Treatment and survivial of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011–1017.

    Google Scholar 

  88. Coronary Drug Project Research Group. Coronary Drug Project; Initial findings leading to modifications of its research protocol. JAMA 1970; 214: 1303–1313.

    Article  Google Scholar 

  89. Coronary Drug Project Research Group. Coronary Drug Project; Findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA 1973; 226: 652–657.

    Article  Google Scholar 

  90. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984; 25: 1017–1058.

    PubMed  CAS  Google Scholar 

  91. Applebaum-Bowden D, Haffner SM, Hazzard W. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol. Metabolism 1987; 36: 949–952.

    Article  PubMed  CAS  Google Scholar 

  92. Colvin PL, Auerback BJ, Case LD, Hazzard WR, Applebaum-Bowden D. Dose-response relationship between sex-hormone induced change in hepatic triglyceride lipase and high-density cholesterol in postmenopausal women. Metabolism 1991; 40: 1052–1056.

    Article  PubMed  CAS  Google Scholar 

  93. Sacks FM,Walsh BW. Effects of reproductive hormones on serum lipoproteins: unresolved issues in biology and clinical practice. Ann NY Acad Sci 1990; 592: 273–285.

    Google Scholar 

  94. Applebaum-Bowden D, Goldberg AP, Pyalisto OJ, Brunzell JD, Hazzard WR. Effect of estrogen on post-heparin hepatic lipase. J Clin Invest 1977; 59: 601–608.

    Article  Google Scholar 

  95. Frazer KA, Narla G, Zhang JL, Rubin EM. Apoliprotein (a) gene is regulated by sex hormones and acute phase inducers in YAC transgenic mice. Nature Genet 1995; 9: 424–431.

    Article  PubMed  CAS  Google Scholar 

  96. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358–4365.

    Article  PubMed  CAS  Google Scholar 

  97. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16: 991–997.

    PubMed  CAS  Google Scholar 

  98. Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A, et al. Androgen treatment of abdominally obese men. Obes Res 1993; 1: 245–251.

    PubMed  CAS  Google Scholar 

  99. Despres J-P, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497–511.

    Article  PubMed  CAS  Google Scholar 

  100. Peiris AN, Sothmann MS, Hoffmann RG, Hennes M, Wilson CR, Gustafson AB, Kissebah AH. Adiposity, fat distribution, and cardiovascular risk. Ann Int Med 1989; 110: 867–872.

    PubMed  CAS  Google Scholar 

  101. Ferenchik G, Schwartz D, Ball M, Schwartz K. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci 1992; 302: 78–82.

    Article  Google Scholar 

  102. McNutt RA, Ferenchik GS Kirlin PC, Hamlin NJ. Acute myocardial infarction in a 22 year old world class weight lifter using anabolic steroids. Am J Cardiol 1992; 62: 164.

    Article  Google Scholar 

  103. Frankle MA, Eichberg R, Zachariah SB. Anabolic androgenic steroids and a stroke in an athlete: case report. Arch Phys Med Rehabil 1988; 69: 632–633.

    PubMed  CAS  Google Scholar 

  104. Nguyen T, Goldschmidt-Clermont PJ, Bray PF, Dobs A. Effect of exogenous testosterone administration on platelet aggregation as a marker of clotting function. Program of the 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, June 11–14, 1997, p. 214.

    Google Scholar 

  105. Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated relaxation following acute estrogen withdrawal. Circulation 1994; 90: 1964–1968.

    Article  PubMed  CAS  Google Scholar 

  106. Wagner JD, Clarkson TB, St. Clair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces LDL accululation in the coronary arteries of surgically postmenopausal cymolgus monkeys. J Clin Invest 1991; 88: 1995–2002.

    Article  PubMed  CAS  Google Scholar 

  107. Adams RN, Williams K, Kaplan JR. Effect of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 1995; 15: 562–570.

    Article  PubMed  CAS  Google Scholar 

  108. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995; 91: 1154–1160.

    Article  PubMed  CAS  Google Scholar 

  109. Fujimoto R, Morimoto I, Morita E, Sugimoto H, Ito Y, Sumiya E. Androgen receptors, 5 alpha reductase activity and androgen dependent proliferation of vascular smooth muscle cells. J Steroid Biochem Molec Biol 1994; 50: 169–174.

    Article  PubMed  CAS  Google Scholar 

  110. Larsen BA, Nordestgaard BG, Stender S, Kjeldsen K. Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 1993; 99: 79–86.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Carrie J. Bagatell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William J. Bremner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Physiology, The University of Tennessee, Memphis, TN, USA

    Leonard Share PhD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bagatell, C.J., Bremner, W.J. (1999). Androgen and Estrogen Effects on Plasma Lipids in Men. In: Share, L. (eds) Hormones and the Heart in Health and Disease. Contemporary Endocrinology, vol 21. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-708-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-708-6_14

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5420-9

  • Online ISBN: 978-1-59259-708-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation